The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

OctreoScan     2-[2-[[1-[[10-(4-aminobutyl)- 16-benzyl-4...

Synonyms: AC1MIXSA, MP-1727, LS-186657, D02108, 159201-00-0, ...
This record was replaced with 636392.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of DTPA-SMS


Psychiatry related information on DTPA-SMS


High impact information on DTPA-SMS


Chemical compound and disease context of DTPA-SMS


Biological context of DTPA-SMS


Anatomical context of DTPA-SMS


Associations of DTPA-SMS with other chemical compounds


Gene context of DTPA-SMS

  • The most frequently used peptides in the clinic are analogs of somatostatin (SRIF), e.g. OctreoScan, which contain chelators for the radioisotopes 111In, 86Y, 90Y, 67Ga, 68Ga and 64Cu or for 99mTc and 188Re. and were labelled with the halogens 123I and 18F [26].
  • Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide [8].
  • SSTR2-infected tumors were visible on imaging 6 days after VV injection and could be visualized for up to 3 weeks post-viral injection using repeat injections of 111In-pentetreotide [8].
  • Nevertheless, DOTATOC was clearly superior to the other DOTA-somatostatin analogs tested, as well as OctreoScan, as indicated by the highest tumor-to-nontarget-tissue ratio, including the tumor-to-SSTR-positive-tissue ratios [27].
  • In agreement with reports showing somatostatin receptors on the cell membrane of ectopically secreting ACTH tumours, scintigraphy was performed after intravenous injection of 111 MBq 111In-pentetreotide (OCT) [28].

Analytical, diagnostic and therapeutic context of DTPA-SMS


  1. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors. Scherübl, H., Bäder, M., Fett, U., Hamm, B., Schmidt-Gayk, H., Koppenhagen, K., Dop, F.J., Riecken, E.O., Wiedenmann, B. Gastroenterology (1993) [Pubmed]
  2. Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Groupe D'etude Du Syndrome De Zollinger-Ellison. Cadiot, G., Lebtahi, R., Sarda, L., Bonnaud, G., Marmuse, J.P., Vissuzaine, C., Ruszniewski, P., Le Guludec, D., Mignon, M. Gastroenterology (1996) [Pubmed]
  3. Localisation of mesenchymal tumours by somatostatin receptor imaging. Jan de Beur, S.M., Streeten, E.A., Civelek, A.C., McCarthy, E.F., Uribe, L., Marx, S.J., Onobrakpeya, O., Raisz, L.G., Watts, N.B., Sharon, M., Levine, M.A. Lancet (2002) [Pubmed]
  4. Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy. Nilsson, S., Reubi, J.C., Kalkner, K.M., Laissue, J.A., Horisberger, U., Olerud, C., Westlin, J.E. Cancer Res. (1995) [Pubmed]
  5. Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression. Rostomily, R.C., Elias, M., Deng, M., Elias, P., Born, D.E., Muballe, D., Silbergeld, D.L., Futran, N., Weymuller, E.A., Mankoff, D.A., Eary, J. Head & neck. (2006) [Pubmed]
  6. Current status of gastrointestinal carcinoids. Modlin, I.M., Kidd, M., Latich, I., Zikusoka, M.N., Shapiro, M.D. Gastroenterology (2005) [Pubmed]
  7. Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid. Zatelli, M.C., Maffei, P., Piccin, D., Martini, C., Rea, F., Rubello, D., Margutti, A., Culler, M.D., Sicolo, N., degli Uberti, E.C. J. Clin. Endocrinol. Metab. (2005) [Pubmed]
  8. Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. McCart, J.A., Mehta, N., Scollard, D., Reilly, R.M., Carrasquillo, J.A., Tang, N., Deng, H., Miller, M., Xu, H., Libutti, S.K., Alexander, H.R., Bartlett, D.L. Mol. Ther. (2004) [Pubmed]
  9. Indium-111-pentetreotide imaging in intra-axial brain tumors: comparison with thallium-201 SPECT and MRI. Lee, J.D., Kim, D.I., Lee, J.T., Chang, J.W., Park, C.Y. J. Nucl. Med. (1995) [Pubmed]
  10. Octreoscan in patients with bronchial carcinoid tumours. Granberg, D., Sundin, A., Janson, E.T., Oberg, K., Skogseid, B., Westlin, J.E. Clin. Endocrinol. (Oxf) (2003) [Pubmed]
  11. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Olsen, J.O., Pozderac, R.V., Hinkle, G., Hill, T., O'Dorisio, T.M., Schirmer, W.J., Ellison, E.C., O'Dorisio, M.S. Seminars in nuclear medicine. (1995) [Pubmed]
  12. Somatostatin analogue scintigraphy in Merkel cell tumours. Durani, B.K., Klein, A., Henze, M., Haberkorn, U., Hartschuh, W. Br. J. Dermatol. (2003) [Pubmed]
  13. A metastatic neuroendocrine anaplastic small cell tumor in a patient with multiple endocrine neoplasia type 1 syndrome. Assessment of disease status and response to doxorubicin, cyclophosphamide, etoposide chemotherapy through scintigraphic imaging with 111In-pentetreotide. O'Byrne, K.J., Goggins, M.G., McDonald, G.S., Daly, P.A., Kelleher, D.P., Weir, D.G. Cancer (1994) [Pubmed]
  14. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors. Briganti, V., Sestini, R., Orlando, C., Bernini, G., La Cava, G., Tamburini, A., Raggi, C.C., Serio, M., Maggi, M. Clin. Cancer Res. (1997) [Pubmed]
  15. Indium-111-pentetreotide scintigraphy in children with neuroblast-derived tumors. Manil, L., Edeline, V., Lumbroso, J., Lequen, H., Zucker, J.M. J. Nucl. Med. (1996) [Pubmed]
  16. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Reubi, J.C., Schär, J.C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J.S., Mäcke, H.R. European journal of nuclear medicine. (2000) [Pubmed]
  17. Use of an isotopic somatostatin receptor probe to image gut endocrine tumors. Modlin, I.M., Cornelius, E., Lawton, G.P. Archives of surgery (Chicago, Ill. : 1960) (1995) [Pubmed]
  18. Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Frank-Raue, K., Bihl, H., Dörr, U., Buhr, H., Ziegler, R., Raue, F. Clin. Endocrinol. (Oxf) (1995) [Pubmed]
  19. Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. Krassas, G.E., Pontikides, N., Kaltsas, T., Dumas, A., Frystyk, J., Chen, J.W., Flyvbjerg, A. J. Clin. Endocrinol. Metab. (2003) [Pubmed]
  20. Indium-111-pentetreotide scintigraphy in Graves' ophthalmopathy. Kahaly, G., Diaz, M., Hahn, K., Beyer, J., Bockisch, A. J. Nucl. Med. (1995) [Pubmed]
  21. Strong uptake of 111In-pentetreotide by an MIBG-negative, xenografted neuroblastoma. Manil, L., Perdereau, B., Barbaroux, C., Brixy, F. Int. J. Cancer (1994) [Pubmed]
  22. 111In-pentetreotide scintigraphy in patients with Langerhans' cell histiocytosis. Weinmann, P., Crestani, B., Tazi, A., Genereau, T., Mal, H., Aubier, M., Valeyre, D., Moretti, J.L., Le Guludec, D., Lebtahi, R. J. Nucl. Med. (2000) [Pubmed]
  23. Indium-111-pentetreotide in Graves' disease. Kahaly, G., Görges, R., Diaz, M., Hommel, G., Bockisch, A. J. Nucl. Med. (1998) [Pubmed]
  24. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide. Bangard, M., Béhé, M., Guhlke, S., Otte, R., Bender, H., Maecke, H.R., Biersack, H.J. European journal of nuclear medicine. (2000) [Pubmed]
  25. Octreoscan in thyroid-associated ophthalmopathy. Krassas, G.E. Thyroid (2002) [Pubmed]
  26. Receptor targeting for tumor localisation and therapy with radiopeptides. Heppeler, A., Froidevaux, S., Eberle, A.N., Maecke, H.R. Current medicinal chemistry. (2000) [Pubmed]
  27. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy. Froidevaux, S., Heppeler, A., Eberle, A.N., Meier, A.M., Häusler, M., Beglinger, C., Béhé, M., Powell, P., Mäcke, H.R. Endocrinology (2000) [Pubmed]
  28. Diagnosis and radioguided surgery with 111In-pentetreotide in a patient with paraneoplastic Cushing's syndrome due to a bronchial carcinoid. Mansi, L., Rambaldi, P.F., Panza, N., Esposito, D., Esposito, V., Pastore, V. Eur. J. Endocrinol. (1997) [Pubmed]
  29. Prediction of efficacy of octreotide therapy in patients with acromegaly. Colao, A., Ferone, D., Lastoria, S., Marzullo, P., Cerbone, G., Di Sarno, A., Longobardi, S., Merola, B., Salvatore, M., Lombardi, G. J. Clin. Endocrinol. Metab. (1996) [Pubmed]
  30. Dynamic indium-111-pentetreotide scintigraphy in breast cancer. Bajc, M., Ingvar, C., Palmer, J. J. Nucl. Med. (1996) [Pubmed]
WikiGenes - Universities